Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9UBP6
UPID:
TRMB_HUMAN
Alternative names:
Methyltransferase-like protein 1; mRNA (guanine-N(7)-)-methyltransferase; miRNA (guanine-N(7)-)-methyltransferase; tRNA (guanine(46)-N(7))-methyltransferase; tRNA(m7G46)-methyltransferase
Alternative UPACC:
Q9UBP6; B2RBX1; H7BXF2; Q14105; Q53FS9
Background:
Methyltransferase-like protein 1, known for its pivotal role in RNA modification, catalyzes the formation of N(7)-methylguanine across various RNA species, including tRNAs, mRNAs, and miRNAs. This modification is crucial for the stabilization of tRNA structure, regulation of mRNA translation, and miRNA processing, highlighting its multifaceted role in cellular function.
Therapeutic significance:
Understanding the role of Methyltransferase-like protein 1 could open doors to potential therapeutic strategies. Its involvement in fundamental RNA processes suggests its potential as a target in diseases where these pathways are dysregulated.